Design Therapeutics, Inc. (DSGN) Stock Price & Analysis
Design Therapeutics, Inc. (DSGN) rose 0.86% to USD 10.55 as of June 10, 2026 at 02:01 UTC, according to Nexqual real-time market data.
DSGN last closed at USD 10.46; the session ranged USD 10.25–10.84 on volume of 453,185 shares. Market capitalization is $658.92M, with a 52-week range of USD 3.33–17.25 (NMS). Source: Nexqual, June 10, 2026 at 02:01 UTC.
Key Statistics (as of June 10, 2026 at 02:01 UTC)
| Price | USD 10.55 |
|---|---|
| Change | ▲ 0.86% (up) |
| Previous Close | USD 10.46 |
| Open | USD 10.63 |
| Day Range | USD 10.25 – 10.84 |
| 52-Week Range | USD 3.33 – 17.25 |
| Volume | 453,185 shares |
| Market Cap | $658.92M |
| Exchange | NMS |
Technical Analysis (DSGN)
Nexqual's technical model rates DSGN "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:01 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 40.72 (neutral) |
| vs SMA50 | Below (USD 12.38) |
| MACD | -0.67 (negative) |
Analyst Ratings (DSGN)
Wall Street analysts rate DSGN "Strong Buy" based on 6 analysts, with a mean price target of USD 21 (range USD 20–22), per Nexqual as of June 10, 2026 at 02:01 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 21 |
| High Target | USD 22 |
| Low Target | USD 20 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (DSGN)
| Next Earnings Date | 2026-04-28 |
|---|---|
| EPS Estimate | USD -0.34 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.29 vs est -0.33 ▲ beat |
| 2025-12-31 | USD -0.27 vs est -0.35 ▲ beat |
| 2025-09-30 | USD -0.3 vs est -0.34 ▲ beat |
| 2025-06-30 | USD -0.34 vs est -0.33 ▼ miss |
Source: Nexqual, June 10, 2026 at 02:01 UTC.
Financials & Fundamentals (DSGN)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -31.26% |
| Debt / Equity | 1.25 |
| Current Ratio | 22.28 |
| Total Cash | $222.82M |
| Total Debt | $2.73M |
| Free Cash Flow | $-31.56M |
Source: Nexqual, June 10, 2026 at 02:01 UTC.
Financial Health Score (DSGN)
Nexqual rates Design Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:01 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $223M cash vs $3M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$54M |
| Efficiency | Critical — ROE -31%, ROA -20.9% |
Ownership (DSGN)
| Insider Ownership | +31.93% |
|---|---|
| Institutional Ownership | +61.33% |
| Shares Outstanding | 62.46M |
| Float | 35.36M |
| Short % of Float | +8.23% |
Source: Nexqual, June 10, 2026 at 02:01 UTC.
Leadership (DSGN)
Design Therapeutics, Inc. is led by Pratik Shah (age 55), Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson, per Nexqual as of June 10, 2026 at 02:01 UTC.
| Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson | Pratik Shah (age 55) |
|---|---|
| Chief Operating Officer | Sean Jeffries (age 45) |
| Chief Technology Officer | Doane Chilcoat |
| Chief Scientific Officer | Tadimeti S. Rao |
Major Backers & Investors (DSGN)
Notable institutional backers of Design Therapeutics, Inc. include SR One Capital Management, LP, RA Capital Management, L.P., Point72 Asset Management, L.P., according to Nexqual as of June 10, 2026 at 02:01 UTC.
Active Investors
| Investor | Stake |
|---|---|
| SR One Capital Management, LP | 10.45% |
| RA Capital Management, L.P. | 4.76% |
| Point72 Asset Management, L.P. | 4.36% |
| Baker Bros. Advisors, LP | 4.14% |
| Logos Global Management LP | 3.12% |
| Driehaus Capital Management, LLC | 2.79% |
| Vivo Capital, LLC | 2.58% |
| Almitas Capital LLC | 2.45% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 5.04% |
| Vanguard Group | 4.27% |
Source: Nexqual, June 10, 2026 at 02:01 UTC.
From Design Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-09)
Key Strengths & Strategy (as disclosed to the SEC)
- Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.
- The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CGEM | Cullinan Therapeutics, Inc. | USD 13.18 | ▼ 2.44% |
| EWTX | Edgewise Therapeutics, Inc. | USD 34.06 | ▼ 4.3% |
| IMCR | Immunocore Holdings plc | USD 28.52 | ▲ 0.81% |
| GLUE | Monte Rosa Therapeutics, Inc. | USD 16.61 | ▲ 1.47% |
| FHTX | Foghorn Therapeutics Inc. | USD 3.87 | ▲ 3.75% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:01 UTC. This page is informational and not investment advice.